EU Approves Dupilumab (Dupixent) for Atopic Dermatitis

The European Commission has granted marketing authorization to dupilumab for adults with moderate to severe atopic dermatitis, according to a company news release.
International Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply